Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of lab testing services specialist Bio-Reference Laboratories
So what: Driven by a solid 25% increase in revenue, Bio-Reference posted second-quarter earnings of $0.26 per share, versus the average analyst estimate of $0.24 per share. If your initial reaction is that a $0.02 earnings beat doesn't exactly justify a double-digit price rally, Mr. Market has already come around to your way of thinking. Since the opening spike, the shares have quickly sold off and are now up only 2.4% at the time of this writing.
Now what: I'd take this midday price weakness as a tempting buy-in point. Given the strong operating momentum (patients serviced increased 25%, as well) and demographic tailwinds working in its favor, Bio-Reference seems like a good bet to keep delivering solid top- and bottom-line growth in the foreseeable future. More importantly, with a PEG ratio in line with larger rivals LabCorp
Interested in more info on Bio-Reference? Add it to your watchlist.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of Bio-Reference. Motley Fool newsletter services have recommended buying shares of LabCorp and Quest. Try any of our Foolish newsletter services free for 30 days.
More from The Motley Fool
Why Shares in Bio-Reference Laboratories Inc. Are Soaring Higher
Opko Health Inc. has agreed to acquire Bio-Reference Laboratories Inc. in a deal worth $1.47 billion.
Why Bio-Reference Laboratories, Ciena, and Halozyme Therapeutics Are Today's 3 Best Stocks
Despite a rise in jobless claims and a wild move by the ECB, the S&P 500 surges to an all-time record close. In the meantime, Bio-Reference, Ciena, and Halozyme all rise by double-digit percentages.
Why Bio-Reference Laboratories Inc. Shares Surged
Bio-Reference shares surge after reporting better-than-expected second-quarter results. Find out if the good times can continue for shareholders.